Krystal Biotech, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Krish S. Krishnan and Suma M. Krishnan jointly report beneficial ownership of 3,388,283 shares, representing 11.5% of Krystal Biotech, Inc. common stock.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 5.05% of Krystal Biotech Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Krystal Biotech Inc. common stock following an internal realignment.
NASDAQ
State Street Corporation has reported a passive beneficial ownership of 4.4% of Krystal Biotech Inc.'s common stock as of December 31, 2024.